12 drug(s) with this reaction
14,011 total reports
Drug Effective For Unapproved Indication has been reported as an adverse reaction across 12 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 14,011 adverse event reports mention drug effective for unapproved indication in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with drug effective for unapproved indication, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have drug effective for unapproved indication listed in their FDA adverse event reports, sorted by report count:
In addition to drug effective for unapproved indication, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
12 drug(s) manufactured by Haleon Us Holdings Llc have drug effective for unapproved indication listed in their FDA adverse event reports: DICLOFENAC SODIUM, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, IBUPROFEN SODIUM, IBUPROFEN TABLETS, COATED, and others.
There are a combined 14,011 reports of drug effective for unapproved indication across 12 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.